Wockhardt Limited (IN:WOCKPHARMA)
:WOCKPHARMA
Want to see IN:WOCKPHARMA full AI Analyst Report?
WOCKPHARMA Stock Chart & Stats
₹1405.55
-₹25.55(-1.72%)
At close: 4:00 PM EST
₹1405.55
-₹25.55(-1.72%)
Day’s Range― - ―
52-Week Range₹1,086.80 - ₹1,870.00
Previous CloseN/A
Volume236.67K
Average Volume (3M)24.00K
Market Cap
₹234.12B
Enterprise Value₹248.36B
Total Cash (Recent Filing)₹9.30B
Total Debt (Recent Filing)₹24.56B
Price to Earnings (P/E)100.2
Beta1.47
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.63
Shares Outstanding162,485,570
10 Day Avg. Volume15,364
30 Day Avg. Volume24,000
Financial Highlights & Ratios
PEG Ratio5.29
Price to Book (P/B)5.18
Price to Sales (P/S)7.42
P/FCF Ratio-85.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginsA materially higher gross margin signals better product mix or cost control at the manufacturing level. Sustained gross margin expansion supports eventual operating leverage, giving the company a clearer path to restore operating profitability if SG&A and other costs are managed consistently.
Reduced Leverage / Stable Capital StructureLower leverage and a >50% equity ratio meaningfully reduce refinancing and interest burdens. Improved capital structure increases financial flexibility for investing in capacity, R&D or M&A and lowers bankruptcy risk, making the business more resilient across cycles.
Positive Revenue GrowthConsistent top-line growth indicates continuing demand for formulations and API products across markets. When combined with margin improvement, steady revenue growth underpins durable recovery potential by providing a larger base to absorb fixed costs and improve operating margins.
Bears Say
Negative Operating And Free Cash FlowNegative operating and free cash flow force reliance on external financing, which can restrict investment in manufacturing, compliance and new product launches. Persistent cash deficits undermine self-funded growth and increase vulnerability to funding cost or availability shifts.
Persistent Net Losses And Weak MarginsOngoing net losses and weak operating margins indicate underlying profitability issues beyond one-off items. This hampers retained earnings, limits reinvestment, and means the business has not yet achieved sustainable earnings power despite revenue and gross margin gains.
Erosion Of Equity And Negative ROEShrinking shareholders' equity and negative ROE reflect capital erosion from repeated losses. This reduces the cushion against shocks, can limit strategic options, and pressures management to either raise fresh capital or materially improve returns to rebuild shareholder value over the medium term.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
Wockhardt Limited lowest stock price was ₹1086.80 and its highest was ₹1870.00 in the past 12 months.
What is Wockhardt Limited’s market cap?
Wockhardt Limited’s market cap is ₹234.12B.
When is Wockhardt Limited’s upcoming earnings report date?
Wockhardt Limited’s upcoming earnings report date is Jun 03, 2026 which is in 34 days.
How were Wockhardt Limited’s earnings last quarter?
Wockhardt Limited released its earnings results on Feb 10, 2026. The company reported ₹3.631 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.631.
Is Wockhardt Limited overvalued?
According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued.
Does Wockhardt Limited pay dividends?
Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here
What is Wockhardt Limited’s EPS estimate?
Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wockhardt Limited have?
Wockhardt Limited has 162,485,570 shares outstanding.
What happened to Wockhardt Limited’s price movement after its last earnings report?
Wockhardt Limited reported an EPS of ₹3.631 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.086%.
Which hedge fund is a major shareholder of Wockhardt Limited?
Currently, no hedge funds are holding shares in IN:WOCKPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Wockhardt Limited
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―